Theravance names Michael Aguiar CEO
This article was originally published in Scrip
San Francisco, California-based Theravance Inc has appointed Michael W Aguiar as president and chief executive officer of the company effective 15 August, and as a member of its board of directors effective immediately. Mr Aguiar will replace Rick E Winningham who has resigned as CEO of Theravance Inc. Mr Winningham will however remain chair of Theravance's board and transition to full time CEO of spin out unit Theravance Biopharma.
You may also be interested in...
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’